Tag: Pharmaceutical AI

Introduction: Why Validate AI Systems in GxP? To validate AI systems in GxP environments, pharmaceutical and biopharmaceutical organizations must establish documented evidence that an AI-enabled system is fit for its intended use, performs reliably within defined limits, and maintains appropriate controls throughout its lifecycle. Artificial intelligence (AI) and machine learning (ML) are transforming pharmaceutical manufacturing, quality control, clinical research, pharmacovigilance, laboratory operations, and regulatory affairs. From automated visual inspection to predictive maintenance and deviation investigation, AI can improve efficiency, identify patterns, and support faster decision-making. However, using AI in a regulated environment introduces important challenges. AI systems may produce variable outputs, rely on complex training datasets, exhibit bias, or change their performance when data and operating conditions evolve. Traditional software validation approaches may not adequately address these additional risks unless they are adapted to the AI system's intended use and characteristics. The European Medicines Agency (EMA) has addressed AI use across the medicinal product lifecycle in its 2024 reflection paper. The US Food and Drug Administration (FDA) has also published guidance and principles concerning AI applications in drug development. These resources reinforce the importance of risk-based assessment, reliable evidence, appropriate documentation, and lifecycle oversight. In this article, we explore seven practical steps to validate AI systems in GxP environments, from defining the User Requirements Specification (URS) to implementing continuous monitoring. Understanding AI Validation in GxP GxP refers to regulated good practices, including Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP). The applicable requirements depend on the organization's activities, system functionality, and regulatory obligations. AI validation is the documented process of establishing confidence that an AI-enabled system consistently performs its intended function and remains suitable for its approved context of use. Depending on the application, validation may need to address: Functional accuracy and reliability. Data integrity, traceability, and security. Model performance and limitations. Human oversight and decision-making. Electronic records and electronic signatures, where applicable. System configuration, interfaces, and access controls. Model updates, retraining, and performance drift. For example, an AI tool used to summarize internal training material may have a different risk profile from an AI model used to identify potentially defective pharmaceutical products or support a critical quality decision. The fundamental principle is to scale validation rigor according to intended use, potential impact, and risk—not simply according to whether a system uses AI. Step 1: Define the User Requirements Specification (URS) The User Requirements Specification establishes what the AI system must do, the conditions under which it will operate, and the controls required for its intended use. A well-written URS provides the foundation for system selection, risk assessment, testing, and final approval. What should an AI URS include? 1. Intended use and scope Clearly describe the business process and the decisions the AI system will support. Define whether its outputs are advisory, require human approval, or directly trigger automated actions. 2. Functional requirements Specify expected functionality, input formats, output formats, processing steps, and integration requirements. 3. Performance requirements Define measurable acceptance criteria appropriate to the application. These could include sensitivity, specificity, false-positive rates, false-negative rates, or prediction error. 4. Data requirements Identify approved data sources, permitted formats, data quality expectations, retention requirements, and applicable privacy controls. 5. Security and auditability Specify user access controls, audit trails, data protection, and record retention requirements where applicable. 6. Human oversight Define who reviews AI-generated recommendations, how exceptions are handled, and who has final decision-making authority. Practical example Suppose a pharmaceutical manufacturer plans to use AI for visual inspection of injectable products. The URS might specify the product types covered, defect categories, image acquisition conditions, minimum acceptable detection performance, escalation procedures, and requirements for qualified human review. The requirements should be measurable wherever possible. Statements such as "the AI must be accurate" are insufficient without a defined evaluation method and acceptance criteria. Step 2: Conduct a Risk Assessment Risk assessment determines how much validation effort is necessary and which controls are essential. When organizations validate AI systems in GxP, they should evaluate both conventional software risks and risks specific to AI, including data bias, model uncertainty, unpredictable outputs, and performance drift. Key risk assessment considerations Risk areaExample riskPotential controlPatient safetyAI fails to identify a critical defectPerformance testing and qualified human reviewProduct qualityIncorrect prediction influences a quality decisionIndependent verification and approval controlsData integrityTraining data or outputs are altered without traceabilityAccess controls and audit trailsModel biasCertain defect types are underrepresented in training dataRepresentative datasets and subgroup testingCybersecurityUnauthorized access to models or source dataAuthentication, access restrictions, and security monitoringModel driftPerformance deteriorates as input conditions changeDefined monitoring thresholds and reassessmentSupplier dependencyVendor changes the underlying model without notificationContractual change notification and supplier oversight Risk assessment should consider the severity of a potential failure, the likelihood of occurrence, the ability to detect the failure, and the effectiveness of existing controls. Organizations can use a documented risk assessment methodology consistent with their quality management system. The resulting risk controls should be traceable to requirements and test evidence. High-risk functions generally require stronger verification, more challenging test scenarios, and clearer approval criteria. Importantly, risk assessment should not be a one-time activity. New data, model changes, process changes, and emerging failure patterns may require reassessment. Step 3: Establish Data Governance and Integrity AI performance depends heavily on the quality, suitability, and representativeness of its data. An AI model may appear successful during development but fail in production if the training dataset does not adequately represent actual operating conditions. Essential data governance controls Data provenance: Document where data originated, how it was collected, and whether its use is authorized. Data quality: Assess completeness, consistency, accuracy, relevance, and potential duplication. Representativeness: Evaluate whether datasets reflect relevant products, equipment, operators, environmental conditions, and defect types. Data segregation: Maintain appropriate separation between training, validation, and independent test datasets to reduce the risk of data leakage. Traceability: Preserve links between data versions, model versions, evaluation results, and approved releases. Privacy and security: Apply suitable safeguards to confidential, personal, clinical, and proprietary information. Data integrity: Ensure records are protected against unauthorized alteration, loss, and inappropriate deletion. Why independent datasets matter Consider an AI model trained to detect particles in pharmaceutical containers. If nearly all training images show large, dark particles, the model may perform poorly when exposed to smaller, translucent, metallic, or low-contrast particles. Independent testing with representative and appropriately challenging samples helps establish whether the model performs reliably beyond its training examples. Data preparation, exclusion criteria, labeling decisions, and known limitations should be documented and justified. Step 4: Develop a Risk-Based Validation Strategy After defining requirements, risks, and data controls, establish a validation strategy that identifies the evidence required to demonstrate fitness for intended use. Traditional Computer System Validation (CSV) principles remain relevant. Risk-based Computer Software Assurance (CSA) concepts may also inform testing approaches where appropriate, but organizations must confirm their applicability to the specific system and regulatory framework. What should the validation strategy cover? System classification and intended use. Supplier assessment and available development evidence. Validation scope and responsibilities. Requirements and risk traceability. Infrastructure, configuration, and interface verification. AI model performance evaluation. Test methods and acceptance criteria. Deviation management and approval. Release criteria and lifecycle controls. The strategy should distinguish between the underlying software platform and the AI model. A platform may function correctly while its model generates inaccurate predictions. Both system functionality and model performance therefore need appropriate evaluation. Define the context of use The context of use describes the specific purpose for which the model's output will be relied upon. For example, an AI model that recommends possible causes of laboratory deviations may be acceptable as an investigative support tool when a qualified analyst reviews its suggestions. The same model may be unsuitable for independently approving a batch or closing a deviation. Validation must demonstrate suitability for the actual intended use, not merely show that the model produces plausible outputs. Step 5: Execute Comprehensive AI Testing Testing provides objective evidence that the system meets its approved requirements and performs acceptably under expected and challenging conditions. AI testing should address the complete system, including the model, data pipeline, user interface, integrations, access controls, and human-AI workflow. Essential AI validation tests 1. Functional testing Verify that the system accepts valid inputs, processes them correctly, and produces outputs in the required format. 2. Performance testing Evaluate predefined metrics against justified acceptance criteria. Select metrics that reflect the consequences of false positives, false negatives, or incorrect predictions. 3. Boundary and challenge testing Test unusual inputs, difficult cases, incomplete records, poor-quality images, and conditions near defined operating limits. 4. Robustness testing Evaluate how performance responds to relevant variations in input data, equipment, operating environments, or other expected conditions. 5. Bias and subgroup testing Investigate whether model performance varies materially across relevant product types, defect categories, data sources, or operating conditions. 6. Security and access testing Verify authentication, permissions, data protection, audit trails, and other applicable controls. 7. Integration testing Confirm that data moves correctly between connected systems and that errors, interruptions, and interface failures are appropriately handled. 8. Human oversight testing Verify that users can identify AI-generated outputs, review supporting information where available, reject unsuitable recommendations, and escalate exceptions. Example: AI-powered pharmaceutical visual inspection A manufacturer introducing AI-assisted inspection could test the model using representative defect-free units and seeded defects across justified particle sizes, colors, shapes, and contrast levels. The protocol should define: Sample selection and preparation. Reference classifications established through an appropriate method. Required performance metrics and acceptance criteria. Treatment of false-positive and false-negative results. Repeatability and robustness conditions. Handling of uncertain or out-of-scope cases. Documentation and approval of deviations. Acceptance criteria must be justified before testing. They should not be changed retrospectively simply because the model fails to meet them. For additional background on pharmaceutical computer system assurance, see the related article on CSV vs CSA in Pharma. Step 6: Prepare Documentation and Obtain Approval A validated AI system requires a clear, reviewable evidence trail. Documentation should allow an independent reviewer to understand what was validated, why the selected approach was appropriate, which risks were identified, how testing was performed, and whether acceptance criteria were met. Essential AI validation documents Validation plan or validation strategy. User Requirements Specification (URS). Functional and technical specifications, where applicable. Supplier assessment and relevant supplier documentation. Risk assessment and risk control records. Data governance and model documentation. Test protocols, test results, and supporting evidence. Requirements-to-test traceability matrix. Deviations, investigations, and corrective actions. Validation summary report. Standard operating procedures and training records. Change control and ongoing monitoring procedures. Additional records may be necessary depending on the system's intended use, architecture, applicable regulations, and quality procedures. What should the validation summary report confirm? The report should summarize the validation activities performed, results against approved acceptance criteria, unresolved deviations, residual risks, and the rationale for release or rejection. Approval should involve the appropriate process owner, system owner, technical experts, and Quality Assurance representatives according to established procedures. A system should not enter regulated production use until the required approvals and release conditions have been satisfied. Step 7: Implement Continuous Monitoring and Change Control AI validation does not end when a system is approved for use. Unlike conventional software that may operate with largely fixed logic, some AI systems can be affected by changes in data distributions, upstream processes, external services, or model versions. Even a model that does not learn automatically may experience declining performance as operating conditions change. Establish an AI monitoring plan Performance monitoring: Track relevant metrics using suitable reference data, verified outcomes, or other justified evaluation methods. Drift detection: Define methods for identifying material changes in input data or model behavior. Exception management: Investigate unexpected outputs, recurring errors, and potential quality events. Change control: Assess model updates, retraining, configuration changes, new integrations, and supplier releases before implementation. Periodic review: Reassess whether the system remains suitable for its approved context of use. Incident response: Define actions for unacceptable performance, including escalation, restricted use, rollback, or temporary suspension. Revalidation: Determine when changes or new evidence require partial or more extensive revalidation. What about generative AI? Generative AI introduces additional considerations because outputs may vary between runs and can contain fabricated facts, unsupported conclusions, or misleading summaries. For a generative AI tool used to assist with deviation investigations, controls may include restricting approved source documents, testing representative prompts, checking citations and factual accuracy, preventing unauthorized disclosure, and requiring qualified personnel to verify conclusions. If the system's underlying model or configuration changes, the organization should assess the impact and determine the necessary testing before approving continued use. Continuous monitoring should be proportionate to risk, supported by documented responsibilities, and integrated into the pharmaceutical quality management system. Common Challenges in AI Validation Organizations may encounter several challenges when validating AI systems in GxP environments. Black-box models: Complex models may not provide easily interpretable reasoning. Mitigation includes documenting the model's limitations, evaluating outputs against independent evidence, and establishing appropriate human oversight. Limited training data: Small or unrepresentative datasets can produce unreliable results. Improve data quality, expand representative test coverage, and clearly document remaining limitations. Unclear acceptance criteria: Vague performance expectations make validation difficult to defend. Define measurable, scientifically justified criteria before execution. Frequent vendor updates: Cloud-based AI services may change independently of local release schedules. Establish supplier agreements, version visibility where available, change notification, and reassessment procedures. Overreliance on AI outputs: Users may accept recommendations without appropriate scrutiny. Train users to understand limitations and require human approval for decisions where necessary. Insufficient lifecycle governance: Organizations may validate the initial release but neglect ongoing performance. Assign system ownership and establish monitoring, review, and change control responsibilities. AI Validation Checklist Use this checklist when planning an AI implementation in a regulated pharmaceutical or biopharmaceutical environment. Intended use and context of use are documented. URS requirements are clear and testable. System risks and AI-specific risks have been assessed. Data provenance, quality, and integrity controls are established. Training, validation, and test datasets are appropriately controlled. Performance metrics and acceptance criteria are justified. Functional, performance, robustness, and security testing are completed as applicable. Human oversight and exception handling are verified. Requirements, risks, and test evidence are traceable. Deviations are investigated and appropriately resolved. Validation documentation is reviewed and approved. Change control and supplier oversight are implemented. Monitoring, periodic review, and incident response are defined. Personnel are trained for their assigned responsibilities. The checklist is a planning aid, not a substitute for a system-specific assessment of applicable regulatory requirements. Regulatory References and Further Reading Organizations should consult current, applicable regulations and guidance when developing their AI validation approach. European Medicines Agency: Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle. This document discusses AI and machine learning applications across the medicinal product lifecycle. US Food and Drug Administration: Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. This January 2025 draft guidance addresses credibility assessment for AI models used to support regulatory decisions about drugs and biological products. Consult the FDA page for the latest status. US Food and Drug Administration: Computer Software Assurance for Production and Quality Management System Software. This guidance addresses risk-based assurance for software used in medical-device production and quality management systems. Its applicability should be assessed against the intended use and regulatory scope; it is not a universal AI-specific validation standard. GauravDakshini.com: CSV vs CSA in Pharma. Explore the differences between traditional computer system validation and computer software assurance approaches. Conclusion: Build Trustworthy AI Through Risk-Based Validation To validate AI systems in GxP environments successfully, organizations must combine sound requirements engineering, risk-based testing, reliable data governance, documented evidence, and continuous lifecycle oversight. The seven steps—URS, risk assessment, data governance, validation strategy, comprehensive testing, documentation, and continuous monitoring—provide a structured approach to evaluating AI systems according to their intended use and potential impact on product quality, patient safety, and data integrity. AI can support more efficient pharmaceutical operations, but adopting a new technology does not remove existing quality responsibilities. Organizations remain accountable for ensuring that regulated processes operate under appropriate controls and that AI-generated outputs are used within validated boundaries. The goal is not simply to demonstrate that an AI model works. It is to establish documented confidence that the complete system is fit for purpose, its limitations are understood, and its performance remains acceptable throughout its lifecycle. For pharmaceutical professionals, validation specialists, and digital transformation leaders, developing these capabilities is an important step toward responsible AI adoption in regulated industries. Explore more pharmaceutical digital transformation and computer system validation resources at GauravDakshini.com. Frequently Asked Questions (FAQs) 1. What does it mean to validate AI systems in GxP? It means establishing documented evidence that an AI-enabled system is suitable for its intended regulated use, meets predefined requirements, performs within justified acceptance criteria, and remains controlled throughout its lifecycle. 2. Is AI validation different from traditional computer system validation? AI validation retains core CSV principles, including requirements, risk assessment, testing, traceability, and documentation. It may also require additional evaluation of training data, model performance, bias, uncertainty, explainability, and performance drift. 3. What documents are required for AI validation in pharma? Typical documents include the URS, validation plan, risk assessment, data and model documentation, test protocols and results, traceability matrix, deviation records, validation summary report, and lifecycle monitoring procedures. The precise documentation set depends on intended use and applicable requirements. 4. How should AI models be tested in a GxP environment? Testing should use appropriate, representative datasets and predefined acceptance criteria. Depending on intended use, it may include functional testing, performance metrics, challenge cases, robustness, bias assessment, integration testing, security controls, and verification of human oversight. 5. Does every AI system require the same level of validation? No. Validation rigor should reflect the intended use, applicable regulatory requirements, system complexity, and potential impact of failure. An AI tool supporting a low-risk administrative task may require different controls from a system influencing product release or patient safety. 6. How often should an AI system be revalidated? There is no single universal interval for every AI system. Organizations should define periodic reviews and event-driven reassessment based on risk, observed performance, data drift, model or configuration changes, supplier updates, and changes in intended use. 7. Can generative AI be used in GxP processes? Generative AI may be used where its intended application is appropriately assessed and controlled. Depending on the use case, safeguards may include approved information sources, access restrictions, output verification, human review, auditability, and change control. Its suitability must be established for the specific process rather than assumed from general model performance. Editorial note: This article provides general educational information and is not a substitute for applicable regulations, regulatory guidance, or an organization's approved quality procedures. Validation decisions should be made by appropriately qualified personnel based on the specific system and intended use.

Tag: Pharmaceutical AI

Validate AI Systems in GxP: 7 Powerful Steps for Reliable Compliance

CONTACT US

QUICK LINKS

LEGAL PAGES

ABOUT

Learn on the go through our Skillup to Scaleup Movement!

© 2024 GAURAV DAKSHINI. All Rights Reserved. Managed by CONFIANCA TECHNOLOGIES LLP